LOXO ONCOLOGY, INC. LOXO Balance Sheet

Loxo oncology, inc. (LOXO)

Balance Sheet / Yearly

Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Dec'13
Assets
Current assets:
Cash and cash equivalents
136,109	147,650	103,780	142,025	80,419	260,267	48,496	30,376	51,929	52,906	47,547	68,177	34,409	36,635	37,255	43,930	118,621	51,304	14,994
Short-term investments
485,890	523,338	606,449	484,175	291,250	207,318	191,819	108,935	103,608	118,831	97,296	85,715	59,013	65,165	60,697	62,362	-	-	-
Receivable from collaboration partner
-	-	4,529	150,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Prepaid expenses with related party
-	-	-	-	-	-	-	-	-	-	-	922	922	972	658	663	-	-	-
Other prepaid expenses and current assets
6,309	5,749	5,891	5,607	4,942	3,831	4,084	2,483	4,094	2,753	2,411	1,830	2,062	410	555	821	1,415	651	17
Total current assets
628,308	676,737	720,649	781,807	376,611	471,416	244,399	141,794	159,631	174,490	147,254	156,644	96,406	103,182	99,165	107,776	120,036	51,955	15,011
Long term investments
25,603	35,413	25,355	-	33,606	-	3,984	2,499	1,002	-	-	0	-	-	9,650	6,648	-	-	-
Property and equipment, net
4,253	3,333	1,578	912	566	364	328	248	269	291	303	88	74	78	31	12	13	7	-
Other assets
1,064	1,027	1,027	723	723	657	653	771	566	440	496	726	222	23	23	23	23	23	11
Deferred initial public offering costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	927	-
Total assets
659,228	716,510	748,609	783,442	411,506	472,437	249,364	145,312	161,468	175,221	148,053	157,458	96,702	103,283	108,869	114,459	120,072	52,912	15,022
Liabilities and stockholders' equity
Current liabilities:
Accounts payable
2,018	4,789	5,796	3,996	1,829	2,175	1,253	1,061	1,021	677	758	269	731	415	285	239	207	652	221
Payable due to collaboration partner
2,576	593	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses and other current liabilities
43,739	34,386	22,546	22,537	15,641	9,008	9,155	14,083	5,633	5,119	2,147	2,584	2,108	1,403	1,024	1,548	520	581	189
Current portion of deferred revenue
125,436	146,139	176,157	195,037	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total current liabilities
173,769	185,907	204,499	221,570	-	-	-	15,144	-	-	-	-	-	-	-	-	-	-	-
Non-current portion of deferred revenue
106,244	138,479	159,689	183,662	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total liabilities
280,013	324,386	364,188	405,232	17,470	11,183	10,408	15,144	6,654	5,796	2,905	2,853	2,839	1,818	1,309	1,787	727	1,233	410
Commitments and contingencies
0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Redeemable convertible preferred stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	68,049	24,843
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
0	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	0	-	-
Common stock, $0.0001 par value; 125,000,000 shares authorized; 30,566,797 and 29,991,884 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively
3	3	3	3	3	3	2	2	2	2	2	2	2	2	2	2	2	0	-
Additional paid-in capital
710,137	695,996	676,771	666,891	661,613	655,581	402,883	269,423	266,798	263,680	223,540	221,457	147,825	146,660	144,709	143,660	143,183	727	59
Accumulated deficit
-330,460	-303,396	-291,670	-288,112	-267,484	-194,165	-163,764	-139,236	-112,042	-94,351	-78,435	-66,838	-53,971	-45,200	-37,144	-30,962	-23,840	-17,097	-10,290
Accumulated other comprehensive loss
-465	-479	-683	-572	-96	-165	-165	-21	56	94	41	-16	7	3	-7	-28	-	-	-
Total stockholders' equity
379,215	392,124	384,421	378,210	394,036	461,254	238,956	130,168	154,814	169,425	145,148	154,605	93,863	101,465	107,560	112,672	119,345	-16,370	-10,231
Total liabilities and stockholders' equity
659,228	716,510	748,609	783,442	411,506	472,437	249,364	145,312	161,468	175,221	148,053	157,458	96,702	103,283	108,869	114,459	120,072	52,912	15,022